Your shopping cart is currently empty

DS39201083, a Conolidine derivative, is a potent oral analgesic. It does not exhibit agonistic activity at the μ-opioid receptor. DS39201083 is applicable in the study of neurological disorders.
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | 10-14 weeks | 10-14 weeks | |
| 50 mg | Inquiry | 10-14 weeks | 10-14 weeks |
| Description | DS39201083, a Conolidine derivative, is a potent oral analgesic. It does not exhibit agonistic activity at the μ-opioid receptor. DS39201083 is applicable in the study of neurological disorders. |
| In vitro | DS39201083 exhibits an IC50 of 71 μM in μ-opioid receptor (MOR) binding assays; in functional MOR cAMP assays, it shows an EC50 greater than 100 μM and an Emax of 12%. |
| In vivo | DS39201083 (Compound 17a) (30 mg/kg, oral, single dose) effectively inhibits acute pain induced by formalin in mice through a non-opioid mechanism. In the acetic acid-induced writhing test with Slc:ddY mice, DS39201083 demonstrates excellent dose-dependent activity (ED50=7.8 mg/kg; inhibition rates are 23%, 52%, and 94% at 3, 10, and 30 mg/kg, respectively). |
| Molecular Weight | 254.33 |
| Formula | C16H18N2O |
| Cas No. | 2361560-81-6 |
| Smiles | O=C1C=2NC=3C=CC=CC3C2CN4CCC1(C)CC4 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.